ASHBURN, Va., April 23, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the appointment of William Pieroni as Global Strategy and Growth Leader for Insurance Software & Business Process Services (BPS). In this role, he will focus on driving strategy, accelerating growth and delivering long-term industry impact.
"Bill is a proven strategist and respected leader with deep domain expertise and a global perspective. He is a trusted partner, recognized for his strong understanding of client challenges and his collaborative approach to developing tailored solutions," said Ray August, EVP and President, Insurance Software and Business Process Services, DXC. "His appointment reflects our commitment to industry leadership, intelligent growth and long-term value creation. I'm excited to partner with him as we continue to enhance the value we deliver to thousands of customers worldwide."
Pieroni brings more than 25 years of experience leading global organizations at the intersection of insurance, technology, and enterprise transformation. Most recently, he served as CEO of ACORD, the global standards-setting body for the insurance industry, where he also established ACORD Solutions Group, focused on advancing data exchange and platform innovation across the insurance value chain.
He has also held senior executive roles at Marsh McLennan, Aon, State Farm, IBM, Accenture, and McKinsey & Company, where he led enterprise strategy, operations, distribution, and large-scale transformation initiatives across international markets.
At DXC, he will be responsible for defining strategic priorities, guiding global growth initiatives, and strengthening the firm's position as a trusted partner across the global insurance ecosystem. He will lead efforts to deliver competitive differentiation, operational excellence, and sustained value creation across the insurance value chain.
"I'm honored to join DXC at such a pivotal time for the insurance industry," said Bill Pieroni. "DXC has an unrivaled team, a comprehensive solution portfolio, and deep client relationships—supported by one of the industry's broadest global footprints. I look forward to building on that foundation to deliver meaningful outcomes for our clients and the industry."
With over 40 years of innovation in the insurance sector, DXC supports more than 1,000 customers and has processed over 1 billion policies through its solutions. Today, 21 of the world's top 25 insurers trust DXC to deliver mission-critical software and services that solve essential business challenges.
For more information about DXC Insurance Software & BPS, visit here.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world's largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.
Angelena Abate, Media Relations, +1-646-234-8060, Angelena.abate@dxc.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DXC Appoints William Pieroni to Drive Strategy and Growth Across Global Insurance Software and Business Process Services
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
